Arachidonoyl ethanolamide phosphate 

Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype)^[1][2].

Arachidonoyl ethanolamide phosphate (AEA; 1 μM) is shown to induce apoptotic bodies formation and DNA fragmentation, hallmarks of programmed cell death, in human neuroblastoma CHP100 and lymphoma U937 cells^[1].
An anti-proliferative action of Arachidonoyl ethanolamide phosphate in human breast carcinoma cells, due to a CB1-like receptor-mediated inhibition of the action of endogenous prolactin at its receptor. Arachidonoyl ethanolamide phosphate has an activation of cell proliferation in hematopoietic cell lines. Arachidonoyl ethanolamide phosphate is a neuromodulator that mediate a retrograde signaling pathway to modulate neurotransmitter release at the presynaptic terminal^[1].
Arachidonoyl ethanolamide phosphate (0.1-10 μM; for 5 days) time- and concentration-dependently inhibits rat C6 glioma cell proliferation^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

427.51

C₂₂H₃₈NO₅P

183323-26-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. M Maccarrone, et al. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem. 2000 Oct 13;275(41):31938-45.  [Content Brief]

  [2]. S O Jacobsson, et al. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther. 2001 Dec;299(3):951-9.  [Content Brief]